| 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups IE Lundberg, A Tjärnlund, M Bottai, VP Werth, C Pilkington, M De Visser, ... Arthritis & rheumatology 69 (12), 2271-2282, 2017 | 1307 | 2017 |
| Randomized trial of thymectomy in myasthenia gravis GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ... New England Journal of Medicine 375 (6), 511-522, 2016 | 890 | 2016 |
| Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo‐phase trial CV Oddis, AM Reed, R Aggarwal, LG Rider, DP Ascherman, ... Arthritis & Rheumatism 65 (2), 314-324, 2013 | 687 | 2013 |
| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 581 | 2017 |
| Ataluren treatment of patients with nonsense mutation dystrophinopathy K Bushby, R Finkel, B Wong, R Barohn, C Campbell, GP Comi, ... Muscle & nerve 50 (4), 477-487, 2014 | 503 | 2014 |
| Guillain-Barré syndrome and variants MM Dimachkie, RJ Barohn Neurologic clinics 31 (2), 491-510, 2013 | 486 | 2013 |
| Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial CM McDonald, C Campbell, RE Torricelli, RS Finkel, KM Flanigan, ... The Lancet 390 (10101), 1489-1498, 2017 | 445 | 2017 |
| Regional variation of Guillain-Barré syndrome AY Doets, C Verboon, B Van Den Berg, T Harbo, DR Cornblath, ... Brain 141 (10), 2866-2877, 2018 | 294 | 2018 |
| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 272 | 2021 |
| Predictors of clinical improvement in rituximab‐treated refractory adult and juvenile dermatomyositis and adult polymyositis R Aggarwal, A Bandos, AM Reed, DP Ascherman, RJ Barohn, ... Arthritis & rheumatology 66 (3), 740-749, 2014 | 264 | 2014 |
| Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial IN van Schaik, V Bril, N van Geloven, HP Hartung, RA Lewis, G Sobue, ... The Lancet Neurology 17 (1), 35-46, 2018 | 259 | 2018 |
| The MG Composite: A valid and reliable outcome measure for myasthenia gravis Neurology 74 (18), 1434-40, 2010 | 244 | 2010 |
| A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis JF Howard Jr, RJ Barohn, GR Cutter, M Freimer, VC Juel, T Mozaffar, ... Muscle & nerve 48 (1), 76-84, 2013 | 238 | 2013 |
| 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis … R Aggarwal, LG Rider, N Ruperto, N Bayat, B Erman, BM Feldman, ... Arthritis & Rheumatology 69 (5), 898-910, 2017 | 224 | 2017 |
| Clinical findings in MuSK‐antibody positive myasthenia gravis: a US experience M Pasnoor, GI Wolfe, S Nations, J Trivedi, RJ Barohn, L Herbelin, ... Muscle & Nerve: Official Journal of the American Association of …, 2010 | 208 | 2010 |
| Treatment of myasthenia gravis C Farmakidis, M Pasnoor, MM Dimachkie, RJ Barohn Neurologic clinics 36 (2), 311-337, 2018 | 205 | 2018 |
| Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial JM Statland, BN Bundy, Y Wang, DR Rayan, JR Trivedi, VA Sansone, ... Jama 308 (13), 1357-1365, 2012 | 191 | 2012 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 185 | 2019 |
| A genome-wide association study of myasthenia gravis AE Renton, HA Pliner, C Provenzano, A Evoli, R Ricciardi, MA Nalls, ... JAMA neurology 72 (4), 396-404, 2015 | 179 | 2015 |
| Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ... The Lancet Neurology 18 (3), 259-268, 2019 | 175 | 2019 |
Richard BarohnProf of neurology university of missouriVerified email at health.missouri.edu
